Quantcast
Home > Quotes > CDNA
CDNA

CareDx, Inc. Common Stock (CDNA) Quote & Summary Data

$14.74
*  
0.86
5.51%
Get CDNA Alerts
*Delayed - data as of Jun. 20, 2018  -  Find a broker to begin trading CDNA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 15.9207 / $ 14.60
Share Volume
573,321
50 Day Avg. Daily Volume
1,421
Previous Close
$ 15.60
52 Week High / Low
$ 16 / $ 1.04
Market Cap
520,073,660
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
573,321
50 Day Avg. Daily Volume:
1,421

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.25

Trading Range

The current last sale of $14.74 is 1,317.31% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 15.9207 $ 16
 Low: $ 14.60 $ 1.04

Company Description (as filed with the SEC)

We are a global transplant diagnostics company with product offerings along the pre- and post-transplant continuum. We focus on discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. In post-transplant diagnostics, we offer AlloMapĀ®, which is a heart transplant molecular test, and in October 2017 we launched AlloSureĀ®, which is a donor-derived cell free DNA, or "dd-cfDNA" test initially used for kidney transplant patients. In pre-transplant diagnostics, we offer high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. AlloMap AlloMap is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate-to-severe acute cellular rejection.  ... More ...  

Risk Grade

Where does CDNA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 15.66
Open Date:
Jun. 20, 2018
Close Price:
$ 14.74
Close Date:
Jun. 20, 2018

Consensus Recommendation

Analyst Info